Agreement provides acceptance to software for analysing post-translational modifications in Asia
Dortmund, 11 December 2007 - Protagen AG, a arch provider of products, casework and software solutions for protein research, appear today that it has entered into a administration acceding for its Bio-IT software product, Modiro™ – the PTM-Explorer with Tomy Digital Biology Co. Ltd of Tokyo, Japan.
Modiro™ was launched in the bazaar in March this year, and the antecedent sales abstracts accept approved how admired capital software for the qualitative appraisal of post-translational modifications (PTMs) is to protein researchers. Protagen has been acknowledged in accession Modiro™ in both Europe and the USA, and expects accretion sales of the artefact in these markets. Through this acceding with Tomy Digital Biology, Protagen will accretion an accustomed benefactor for the commercialisation of its artefact in the Japanese market.
Tomy Digital Biology has been accustomed for over 40 years and has a acceptable acceptability amidst Japan’s researchers, bartering analysis institutes such as the Riken-Brain Institute and the Osaka National Research Institute. The absolute rights for administration of Modiro™ in Japan accepted to Tomy Digital Biology will advice to defended its arch position as a able provider of Bio-IT software and associated products.
Post-translational protein modifications attune the action of abounding proteins and the appraisal of these changes is of growing accent in the analysis and development of new biologic candidates. Modiro™ enables advisers to analyze decidedly added of these analytical modifications application absolute mass-spectrometry data. In addition, by automating the identification of PTMs, the PTM-Explorer reduces the time bare for protein analysis.
Dr Christoph Hüls, CEO of Protagen, said: “The signing of this commercialisation acceding demonstrates the connected advanced of Protagen into the Asian market, which began with the analysis accord with Kangdi Antibody Biotech and Bejing Proteome Research Centre appear beforehand this year.”
Contact
Dr. Christoph Hüls
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail:info@protagen.com
For English media enquiries
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
Fax: +49 (0) 69 6199 4249
E-Mail: info@holgerbengs.de
About Protagen AG
Protagen (www.protagen.com) is a arch provider of products, casework and software solutions for protein research. Operating internationally to accommodate barter with articles and casework of the accomplished quality, Protagen has offices in Dortmund, Germany and New Jersey, USA. The Company has a decade of acquaintance in applying the a lot of beat protein analysis accoutrement and techniques to advance the ability of the biologic analysis and development process.
As an innovator in protein biochips, Protagen has developed UNIclone®, a apparent adequate belvedere for protein announcement libraries and protein arrays, and UNIchip®, a able and awful able alternation of protein biochip articles for antibiotic development. In addition, it has accustomed UNIarrayTM, a awful able technology belvedere for biomarker analysis on an automated scale. Protagen has afresh accustomed a BioChance Plus admission from the German government to analyze biomarkers for Multiple Sclerosis and Rheumatoid Arthritis.
Protagen provides barter with a adjustable account program, including protein appraisal and identification, cogwheel protein display, antibiotic validation and specification, antigen identification, and abounding abstracts administration services.
Protagen AG is abreast endemic and has bankrupt two costs rounds: at the end of 2004 and in bounce 2006. Shareholders of Protagen AG, besides the founders and the administration team, are S-Venture Capital Dortmund GmbH and MIG AG & Co KG Beteiligungsfonds 1 and 3.
About Tomy Digital Biology Co. Ltd
Tomy Digital Biology (www.digital-biology.co.jp) provides new technologies and solutions for the optimisation of analysis in the activity sciences in the post-genomic era. Various beginning methods from the three areas of in vitro, in vivo and in silico are accumulated to accomplish this. Tomy Digital Biology is the alone aggregation in Japan that food complete solutions of this kind. The Company draws on added than 40 years business acquaintance in the activity sciences arena.
2009年12月16日星期三
Dr. Holger Bengs Biotech Consulting - Protagen raises €1 actor to aggrandize its protein biochips business unit
Dortmund, Germany and New Jersey, USA, 15 January 2008: Protagen AG, a arch provider of products, casework and software solutions for protein research, announces the closing of an acting costs round. The €1 actor aloft will be acclimated to aggrandize the company’s protein biochips business unit.
The basic aloft in this annular has appear from the absolute institutional investors, MIG AG and Co KG Beteiligungsfonds 3, Munich, and S-Venture Capital Dortmund GmbH, as able-bodied as from a new investor, Kreditanstalt für Wiederaufbau (KfW). This latest allotment brings the absolute aggregate of adventure basic costs aloft by Protagen back 2004 to €5.3 million.
The UNIchip® protein biochip ambit was launched assimilate the bazaar in September 2005, and has accomplished accretion appeal from biotech and biologic companies, decidedly in the USA and Europe area Protagen is based. Using this new basic Protagen aims to advantage its arch position in protein biochips to actualize new articles and casework in the across of biomarkers, both apart and in affiliation with biologic partners.
The Company has already created a different protein biochip technology package, UNIarray®, for the analysis and validation of new biomarkers. Following the analytical identification of autoantibodies in accommodating sera, Protagen is able to actualize a protein biochip ancestor for its ally that can be acclimated as a analytic tool, either as allotment of analytic abstraction or for the identification of accommodating cohorts.
Protagen is aswell alive on its own programmes for the development of ancestor affection for assorted sclerosis, rheumatoid arthritis, adolescent idiopathic arthritis and Alzheimer’s disease. The programme for assorted sclerosis is the a lot of advanced, with a ancestor analytic for the ache already accepting activated in ample numbers of patients.
Contact
Dr. Christoph Hüls
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail:info@protagen.com
For media enquiries
Dr. Holger Bengs
Biotech Consulting
Tel:+49 (0) 69 6199 4273
Fax:+49 (0) 69 6199 4249
E-Mail:info@holgerbengs.de
About Protagen AG
Protagen (www.protagen.com) is a arch provider of products, casework and software solutions for protein research. Operating internationally to accommodate barter with articles and casework of the accomplished quality, Protagen has offices in Dortmund, Germany and New Jersey, USA. The Company has a decade of acquaintance in applying the a lot of beat protein analysis accoutrement and techniques to advance the ability of the biologic analysis and development process.
As an innovator in protein biochips, Protagen has developed UNIclone®, a apparent adequate belvedere for protein announcement libraries and protein arrays, and UNIchip®, a able and awful able alternation of protein biochip articles for antibiotic development. In addition, it has accustomed UNIarrayTM, a awful able technology belvedere for biomarker analysis on an automated scale. Protagen has afresh accustomed a BioChance Plus admission from the German government to analyze biomarkers for Multiple Sclerosis and Rheumatoid Arthritis.
Protagen provides barter with a adjustable account program, including protein appraisal and identification, cogwheel protein display, antibiotic validation and specification, antigen identification, and abounding abstracts administration services.
Protagen AG is abreast endemic and has bankrupt three costs rounds: at the end of 2004, in bounce 2006 and in bounce 2008. Shareholders of Protagen AG, besides the founders and the administration team, are S-Venture Capital Dortmund GmbH, MIG AG & Co KG Beteiligungsfonds 1 and 3 and the Kreditanstalt für Wiederaufbau (KfW).
The basic aloft in this annular has appear from the absolute institutional investors, MIG AG and Co KG Beteiligungsfonds 3, Munich, and S-Venture Capital Dortmund GmbH, as able-bodied as from a new investor, Kreditanstalt für Wiederaufbau (KfW). This latest allotment brings the absolute aggregate of adventure basic costs aloft by Protagen back 2004 to €5.3 million.
The UNIchip® protein biochip ambit was launched assimilate the bazaar in September 2005, and has accomplished accretion appeal from biotech and biologic companies, decidedly in the USA and Europe area Protagen is based. Using this new basic Protagen aims to advantage its arch position in protein biochips to actualize new articles and casework in the across of biomarkers, both apart and in affiliation with biologic partners.
The Company has already created a different protein biochip technology package, UNIarray®, for the analysis and validation of new biomarkers. Following the analytical identification of autoantibodies in accommodating sera, Protagen is able to actualize a protein biochip ancestor for its ally that can be acclimated as a analytic tool, either as allotment of analytic abstraction or for the identification of accommodating cohorts.
Protagen is aswell alive on its own programmes for the development of ancestor affection for assorted sclerosis, rheumatoid arthritis, adolescent idiopathic arthritis and Alzheimer’s disease. The programme for assorted sclerosis is the a lot of advanced, with a ancestor analytic for the ache already accepting activated in ample numbers of patients.
Contact
Dr. Christoph Hüls
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail:info@protagen.com
For media enquiries
Dr. Holger Bengs
Biotech Consulting
Tel:+49 (0) 69 6199 4273
Fax:+49 (0) 69 6199 4249
E-Mail:info@holgerbengs.de
About Protagen AG
Protagen (www.protagen.com) is a arch provider of products, casework and software solutions for protein research. Operating internationally to accommodate barter with articles and casework of the accomplished quality, Protagen has offices in Dortmund, Germany and New Jersey, USA. The Company has a decade of acquaintance in applying the a lot of beat protein analysis accoutrement and techniques to advance the ability of the biologic analysis and development process.
As an innovator in protein biochips, Protagen has developed UNIclone®, a apparent adequate belvedere for protein announcement libraries and protein arrays, and UNIchip®, a able and awful able alternation of protein biochip articles for antibiotic development. In addition, it has accustomed UNIarrayTM, a awful able technology belvedere for biomarker analysis on an automated scale. Protagen has afresh accustomed a BioChance Plus admission from the German government to analyze biomarkers for Multiple Sclerosis and Rheumatoid Arthritis.
Protagen provides barter with a adjustable account program, including protein appraisal and identification, cogwheel protein display, antibiotic validation and specification, antigen identification, and abounding abstracts administration services.
Protagen AG is abreast endemic and has bankrupt three costs rounds: at the end of 2004, in bounce 2006 and in bounce 2008. Shareholders of Protagen AG, besides the founders and the administration team, are S-Venture Capital Dortmund GmbH, MIG AG & Co KG Beteiligungsfonds 1 and 3 and the Kreditanstalt für Wiederaufbau (KfW).
Protagen AG - Protagen and GeneBio Sign Distribution Agreement for Modiro®
Dortmund, Germany and Geneva, Switzerland – May 29, 2008 - Protagen AG and Geneva Bioinformatics (GeneBio) SA today appear a administration acceding that allows GeneBio to deliver Protagen’s Modiro, a atypical software apparatus enabling accelerated and automated apprehension of accurate post-translational modifications in MS/MS datasets.
Under the agreement of the agreement, GeneBio will deliver the Modiro amalgamation on a all-around basis; at the aforementioned time, GeneBio and Protagen will coact carefully in adjustment to seamlessly hotlink the Modiro functionalities to GeneBio’s Phenyx software belvedere for MS abstracts analysis.
Post-translational protein modifications attune the action of abounding proteins and the all-embracing appraisal of these changes is of growing accent in the analysis and development of new biologic candidates. Modiro enables advisers to analyze decidedly added of these acute modifications application absolute mass-spectrometry data. In addition, the automated identification of PTMs by Modiro decidedly reduces time and efforts in protein analysis.
Developed in accord with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s acclaimed software belvedere for the identification and assuming of proteins and peptides from accumulation spectrometry data. The Phenyx belvedere is accurately advised to accommodated the circumstantial demands of high-throughput MS abstracts appraisal and activating after-effects appraisal via a customisable architectonics and an avant-garde user affable interface (phenyx.vital-it.ch/pwi).
“We are actual aflame about this accord with GeneBio and accept it will advice to accompany Modiro to advanced ambit of new customers,” said Dr. Christoph Hüls, CEO of Protagen. “We are able-bodied acquainted of the acceptability of both GeneBio and Phenyx aural the industry and feel that our accumulated efforts will advice to authorize Modiro as the gold-standard for PTM analysis. In addition, we attending advanced to alive with the GeneBio aggregation in adjustment to enhance both the Modiro and Phenyx platform.”
“We are admiring to be able to deliver Modiro and plan with Protagen to advice accession the bar in our industry,” said Nasri Nahas, CEO of GeneBio. “The accession of Modiro to our artefact agency and the closing abstruse assets that our companies will allotment through this cooperation will accompany us afterpiece to our ambition of accouterment the a lot of absolute belvedere in the MS field. Phenyx has apparent cogent absorption in the bazaar back its inception; alive with Protagen will body and extend our expertise, thereby bringing us afterpiece to our goals.”
For added advice apropos this administration agreement, for Phenyx or Modiro artefact demonstrations, amuse appointment GeneBio berth #27 at the accessible ASMS Conference on Mass Spectrometry in Denver, Colorado, from June 1-5.
Contact
Protagen AG
Dr. Christoph Hüls
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Germany
Tel: +49 (0) 231 9742 6300
E-Mail: info@protagen.de
GeneBio
Andrew Smith
Marketing Manager
Geneva Bioinformatics S.A.
25 access de Champel
1206 Genf
Switzerland
Tel: +41 (0) 22 702 9900
E-Mail: andrew.smith@genebio.com
Media enquiries:
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
E-Mail: info@holgerbengs.de
About Protagen AG
Protagen (www.protagen.com) is a arch provider of products, casework and software solutions for protein research. Operating internationally to accommodate barter with articles and casework of the accomplished quality, Protagen has offices in Dortmund, Germany and New Jersey, USA. The Company has a decade of acquaintance in applying the a lot of beat protein analysis accoutrement and techniques to advance the ability of the biologic analysis and development process.
As an innovator in protein biochips, Protagen has developed UNIclone®, a apparent adequate belvedere for protein announcement libraries and protein arrays, and UNIchip®, a able and awful able alternation of protein biochip articles for antibiotic development. In addition, it has accustomed UNIarrayTM, a awful able technology belvedere for biomarker analysis on an automated scale.
About GeneBio
Geneva Bioinformatics (GeneBio) SA is a arch bioinformatics aggregation accouterment the activity science association with world-class proteomics software that bridges the gap amid advice acquisition and ability generation. Established in 1997, we focus our ability on protein identification and assuming as able-bodied as proteome imaging, alms audience and ally a top amount of specialization capital to proteomics research. Close ties to bookish aeon and a absolute arrangement of administration and cardinal ally accord us both able acceptance to accurate arete and accustomed bazaar attendance so that we may best serve the accurate community. For added advice about GeneBio, amuse visit: www.genebio.com.
Under the agreement of the agreement, GeneBio will deliver the Modiro amalgamation on a all-around basis; at the aforementioned time, GeneBio and Protagen will coact carefully in adjustment to seamlessly hotlink the Modiro functionalities to GeneBio’s Phenyx software belvedere for MS abstracts analysis.
Post-translational protein modifications attune the action of abounding proteins and the all-embracing appraisal of these changes is of growing accent in the analysis and development of new biologic candidates. Modiro enables advisers to analyze decidedly added of these acute modifications application absolute mass-spectrometry data. In addition, the automated identification of PTMs by Modiro decidedly reduces time and efforts in protein analysis.
Developed in accord with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s acclaimed software belvedere for the identification and assuming of proteins and peptides from accumulation spectrometry data. The Phenyx belvedere is accurately advised to accommodated the circumstantial demands of high-throughput MS abstracts appraisal and activating after-effects appraisal via a customisable architectonics and an avant-garde user affable interface (phenyx.vital-it.ch/pwi).
“We are actual aflame about this accord with GeneBio and accept it will advice to accompany Modiro to advanced ambit of new customers,” said Dr. Christoph Hüls, CEO of Protagen. “We are able-bodied acquainted of the acceptability of both GeneBio and Phenyx aural the industry and feel that our accumulated efforts will advice to authorize Modiro as the gold-standard for PTM analysis. In addition, we attending advanced to alive with the GeneBio aggregation in adjustment to enhance both the Modiro and Phenyx platform.”
“We are admiring to be able to deliver Modiro and plan with Protagen to advice accession the bar in our industry,” said Nasri Nahas, CEO of GeneBio. “The accession of Modiro to our artefact agency and the closing abstruse assets that our companies will allotment through this cooperation will accompany us afterpiece to our ambition of accouterment the a lot of absolute belvedere in the MS field. Phenyx has apparent cogent absorption in the bazaar back its inception; alive with Protagen will body and extend our expertise, thereby bringing us afterpiece to our goals.”
For added advice apropos this administration agreement, for Phenyx or Modiro artefact demonstrations, amuse appointment GeneBio berth #27 at the accessible ASMS Conference on Mass Spectrometry in Denver, Colorado, from June 1-5.
Contact
Protagen AG
Dr. Christoph Hüls
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Germany
Tel: +49 (0) 231 9742 6300
E-Mail: info@protagen.de
GeneBio
Andrew Smith
Marketing Manager
Geneva Bioinformatics S.A.
25 access de Champel
1206 Genf
Switzerland
Tel: +41 (0) 22 702 9900
E-Mail: andrew.smith@genebio.com
Media enquiries:
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
E-Mail: info@holgerbengs.de
About Protagen AG
Protagen (www.protagen.com) is a arch provider of products, casework and software solutions for protein research. Operating internationally to accommodate barter with articles and casework of the accomplished quality, Protagen has offices in Dortmund, Germany and New Jersey, USA. The Company has a decade of acquaintance in applying the a lot of beat protein analysis accoutrement and techniques to advance the ability of the biologic analysis and development process.
As an innovator in protein biochips, Protagen has developed UNIclone®, a apparent adequate belvedere for protein announcement libraries and protein arrays, and UNIchip®, a able and awful able alternation of protein biochip articles for antibiotic development. In addition, it has accustomed UNIarrayTM, a awful able technology belvedere for biomarker analysis on an automated scale.
About GeneBio
Geneva Bioinformatics (GeneBio) SA is a arch bioinformatics aggregation accouterment the activity science association with world-class proteomics software that bridges the gap amid advice acquisition and ability generation. Established in 1997, we focus our ability on protein identification and assuming as able-bodied as proteome imaging, alms audience and ally a top amount of specialization capital to proteomics research. Close ties to bookish aeon and a absolute arrangement of administration and cardinal ally accord us both able acceptance to accurate arete and accustomed bazaar attendance so that we may best serve the accurate community. For added advice about GeneBio, amuse visit: www.genebio.com.
Protagen AG - Protagen closes new annular of costs to strengthen technology position for atypical diagnostics
Dortmund, Germany and New Jersey, USA, August 1, 2008: Protagen AG, a arch provider of GMP adjustable protein analytic services, protein bioinformatics, and protein biochips announces the closing of a new annular of financing. The basic will be acclimated to strengthen and aggrandize the company’s UNIarray® technology position and the development of atypical diagnostics. The basic aloft in this annular has appear from the absolute institutional investors, MIG AG, Munich, S-Venture Capital Dortmund GmbH, and Kreditanstalt für Wiederaufbau (KfW).
Background: UNIarray® is a different technology belvedere for the development of atypical affection based on adumbration specific autoantibody patterns in accommodating sera. These adumbration specific autoantibody patterns were already accurate to be present in several autoimmune diseases, but aswell in cancer, neurodegenerative disorders, and even in allegedly advantageous individuals. Therefore, the analytical and indication-specific assurance of autoantibody patterns will serve as a different base to abode ahead unmet analytic needs. In addition, UNIarray® serves as a belvedere for the development of artefact specific accompaniment affection and accommodating stratification for analytic studies. In-house analysis at Protagen is anon focused on atypical affection for prostate cancer, assorted sclerosis, rheumatoid arthritis, adolescent idiopathic arthritis, Morbus Parkinson, and Alzheimer’s.
At the aforementioned time Dr. Christoph Hüls (CEO) will leave Protagen for clandestine affidavit and will move to a new position in a ample biologic company. The Chairman of the Board of Protagen AG, Prof. Axel Kleemann, abjure the abandonment of Christoph Hüls and the end of a continued and artless cooperation. Dr. Stefan Müllner (CSO) will crop over the position as new CEO.
Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de
Media Enquiries
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
Fax: +49 (0) 69 6199 4249
E-Mail: info@holgerbengs.de
About Protagen AG
Protagen AG (www.protagen.de) is a arch provider of products, casework and software solutions for protein analysis with sites in Dortmund, Germany, and Chester, New Jersey, USA. Technology innovations of Protagen are UNIclone®, a patented belvedere for development and use of protein announcement libraries, and UNIchip®, a able and awful able ancestors of articles for the development of antibodies, as able-bodied as UNIarray®, a different technology abject for the development of new diagnostics.
Background: UNIarray® is a different technology belvedere for the development of atypical affection based on adumbration specific autoantibody patterns in accommodating sera. These adumbration specific autoantibody patterns were already accurate to be present in several autoimmune diseases, but aswell in cancer, neurodegenerative disorders, and even in allegedly advantageous individuals. Therefore, the analytical and indication-specific assurance of autoantibody patterns will serve as a different base to abode ahead unmet analytic needs. In addition, UNIarray® serves as a belvedere for the development of artefact specific accompaniment affection and accommodating stratification for analytic studies. In-house analysis at Protagen is anon focused on atypical affection for prostate cancer, assorted sclerosis, rheumatoid arthritis, adolescent idiopathic arthritis, Morbus Parkinson, and Alzheimer’s.
At the aforementioned time Dr. Christoph Hüls (CEO) will leave Protagen for clandestine affidavit and will move to a new position in a ample biologic company. The Chairman of the Board of Protagen AG, Prof. Axel Kleemann, abjure the abandonment of Christoph Hüls and the end of a continued and artless cooperation. Dr. Stefan Müllner (CSO) will crop over the position as new CEO.
Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de
Media Enquiries
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
Fax: +49 (0) 69 6199 4249
E-Mail: info@holgerbengs.de
About Protagen AG
Protagen AG (www.protagen.de) is a arch provider of products, casework and software solutions for protein analysis with sites in Dortmund, Germany, and Chester, New Jersey, USA. Technology innovations of Protagen are UNIclone®, a patented belvedere for development and use of protein announcement libraries, and UNIchip®, a able and awful able ancestors of articles for the development of antibodies, as able-bodied as UNIarray®, a different technology abject for the development of new diagnostics.
订阅：
博文 (Atom)